Long term oxybutynin use is associated with higher dementia odds in adults over 55. That is an association, not proof the drug causes it. And it does not apply to every bladder medication: in the largest study, two other overactive bladder drugs showed no significant increase.
That last part usually gets left out of the headlines, and it is the part that changes what you might ask your doctor.
This article is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication routine.
Why this question keeps coming up
Overactive bladder is common after 55, and oxybutynin (sold as Ditropan) has been treating it since its initial US approval in 1975. More than a million people in the US take it, so when research connects it to memory problems, the news travels fast.
The concern is real but narrower than most coverage suggests. Oxybutynin belongs to a group called anticholinergics, which block acetylcholine, a chemical messenger your body uses in two very different places. In your bladder it tells the muscle to squeeze. In your brain it helps with memory and learning.
A drug that reaches both places calms your bladder and dampens brain signaling at once. A drug that only reaches your bladder does not. That single difference explains most of what the research found.
What the studies found, drug by drug
The largest analysis is a 2024 study in BMJ Medicine that looked at 170,742 people with dementia and 804,385 matched people without it, using English primary care records. Instead of lumping all bladder drugs together, it reported each one separately.
| Bladder medication | Does it reach the brain? | Dementia odds in the 2024 study |
|---|---|---|
| Oxybutynin (Ditropan) | Yes | Increased. Odds ratio 1.31 and 1.28 at higher cumulative use |
| Tolterodine (Detrol) | Yes | Increased. Odds ratio 1.27 and 1.25 |
| Solifenacin (Vesicare) | Partly | Increased. Odds ratio 1.18 and 1.29 |
| Darifenacin (Enablex) | Designed to avoid it | No significant increase found |
| Trospium (Sanctura) | Barely, if at all | No significant increase found |
An odds ratio of 1.28 means the odds were about 28 percent higher in that group, not that 28 percent of people taking it will develop dementia. Across all anticholinergic bladder drugs combined, the figure was 1.18.
This pattern is not new. A 2019 study in JAMA Internal Medicine covering 58,769 dementia cases found bladder antimuscarinics among the two strongest signals of any drug class it examined, at an odds ratio of 1.65 for the heaviest users.
Here is the twist. That same study found no significant increase for antihistamines at any level of use, including the ones people worry about most. The class that got flagged was the bladder one, not the allergy one. If you have been losing sleep over your nighttime antihistamine while taking a bladder pill daily, the research points the other way.
The two that came out clean, and the reason why
The two drugs with no significant increase are not lucky. They are built differently.
Your brain is wrapped in a filter called the blood brain barrier. Some molecules slip through it easily. Others cannot.
Trospium is what chemists call a quaternary amine. It carries a permanent electrical charge, which makes it water loving and bulky at the barrier. Research in World Journal of Urology measured 200-fold lower brain concentrations for trospium than for oxybutynin at equal doses in mice. In older patients, the same paper reports trospium was "assay undetectable in the cerebrospinal fluid."
Darifenacin takes a different route. Your body has several acetylcholine receptor types. The M3 type runs bladder squeezing. The M1 type sits in the brain and matters for memory. Darifenacin was designed to target M3 while mostly leaving M1 alone. A review in Clinical Interventions in Aging describes darifenacin and solifenacin as "M3-selective receptor antagonists which potentially may be more bladder-specific with reduced tendency for anticholinergic side effects," and notes this selectivity is "of particular importance for older patients who may be more susceptible to cognitive impairment and central nervous system effects."
Oxybutynin does neither. It crosses the barrier, and it blocks M1 along with M3.
So the chemistry predicted the study results before the study existed. Two independent kinds of evidence pointing the same way is a stronger signal than either alone.
One caution: "no significant increase found" is not the same as "proven safe." It means this study did not detect a difference, which is reassuring but narrower.
The Myrbetriq question, answered honestly
People often ask whether mirabegron (Myrbetriq) is the safe alternative. It is a fair question, because mirabegron is not an anticholinergic at all. According to its FDA prescribing information, it is a beta-3 adrenergic agonist that relaxes the bladder muscle through a completely separate pathway.
But the same 2024 study showed higher dementia odds for mirabegron too, at 1.27 and 1.62 depending on how much was used. Taken alone, that looks alarming.
The study authors explain why it appears. They found that "86.2% of individuals prescribed mirabegron (1574 of 1826 patients) had previously used anticholinergic drugs." In other words, most mirabegron users got there after years on a different drug, often because something had already gone wrong. The number reflects their history, not the new medication.
If you see mirabegron listed as a dementia risk somewhere, check whether the source mentions the 86 percent. Most do not.
Why studies disagree with each other
You may find sources saying there is no link at all. They are not making it up.
The 2024 study addresses this, noting that an earlier analysis "did not find a significant increase in the risk of dementia associated with oxybutynin hydrochloride and tolterodine tartrate," and attributing the difference to protopathic bias.
That is simpler than it sounds. Early dementia can cause bladder problems before anyone recognizes the dementia, so the medication gets prescribed because brain changes had already started. Sort the data one way and the drug looks like the cause. Sort it another way and it looks like an early symptom.
Researchers disagree about how much of the signal is which. That is why a 2025 umbrella review in Molecular Psychiatry, pooling 68 separate analyses, rated the anticholinergic evidence as moderate certainty rather than high, advising "avoidance of anticholinergic drugs in cognitive impairment, with assessment of anticholinergic burden and consideration of alternatives."
Moderate certainty is worth acting on. It is not worth panicking over.
What the label already says
You do not have to settle the dementia debate to find something useful. Oxybutynin's own FDA label states that the drug "is associated with anticholinergic central nervous system (CNS) effects," listing "hallucinations, agitation, confusion and somnolence."
The label also tells prescribers to use caution in people who already have dementia and take cholinesterase inhibitors, since the two work against each other, and to watch for these effects especially in the first few months or after a dose increase.
That guidance is printed on the product. It does not depend on how the dementia debate resolves.
The 2023 American Geriatrics Society Beers Criteria, the standard reference for prescribing in older adults, also flags oral bladder antimuscarinics and recommends reviewing a person's total anticholinergic load at medication reviews.
What to do with this
Do not stop taking your medication because of an article. Untreated overactive bladder carries its own risks: a systematic review in Research and Reports in Urology found that across 15 studies, between 18.9 and 50 percent of people with overactive bladder had at least one fall in a year. That decision belongs to you and your prescriber together.
What this research supports is a conversation. Three things worth raising:
- Which bladder drug am I on, and does it reach the brain? The table above is a starting point, not a verdict on your situation.
- What else am I taking that is anticholinergic? This is the part most people miss. The risk in these studies was cumulative across every anticholinergic drug, not from one pill. Some allergy medications, sleep aids, older antidepressants, and drugs like hydroxyzine all count toward the same total.
- Have I noticed anything? New confusion, word finding trouble, or unusual drowsiness are worth reporting, especially if they started within a few months of a new prescription or dose change.
Bring an accurate list. Most people underestimate what they take, especially the over the counter items that never felt like real medication.
How Pillo helps
The burden idea only works if you know the total, and totals are hard to hold in your head when you are managing several medications across different times of day.
Pillo keeps every medication in one list, including the over the counter ones people forget to mention, so you can hand your doctor something accurate instead of rebuilding it from memory in the exam room. Its alarms keep repeating until you mark the dose as taken, so your history reflects what you actually took. If you are not sure whether you already took something, that record answers it.
Looking after a parent or partner? You can track their medications as a separate dependent inside your own app, with their own schedule, and the reminder lands on your phone.
A consistent daily routine makes changes easier to notice, and our medication spacing guide covers fitting a new schedule around what you already take.
FAQ
What overactive bladder medication does not cause dementia?
In the 2024 BMJ Medicine analysis, darifenacin and trospium showed no significant increase in dementia odds, while oxybutynin, tolterodine and solifenacin did. That is not the same as proven safe. Which drug suits a person depends on their other conditions, what else they take, and how well it actually controls symptoms, so this is a prescriber decision rather than a ranking.
Does oxybutynin cause memory loss?
Oxybutynin's FDA label lists confusion and drowsiness among its known central nervous system effects, and large observational studies link long term cumulative use to higher dementia odds, though that is an association across populations rather than a guaranteed outcome for any one person. If your memory feels different since starting it, that is worth telling your doctor or pharmacist.
Is oxybutynin memory loss reversible?
These are two different questions. The confusion and drowsiness listed on the label are recognized drug effects, and the label tells prescribers to consider a dose reduction or stopping the drug if they show up. That instruction only makes sense if those effects are expected to ease. Dementia risk in the studies is a separate, longer term question the research does not answer for individuals, and either way this is not something to test by stopping on your own.
Does Myrbetriq cause dementia?
Mirabegron is a beta-3 adrenergic agonist and has no anticholinergic activity, so there is no known mechanism for it to affect memory the way oxybutynin can. It did show higher dementia odds in the 2024 study, but the authors reported that 86.2 percent of mirabegron users had previously taken anticholinergic drugs, which likely explains the number. Any source citing that figure without the explanation is giving you half the finding.
What counts as long term use?
The elevated odds appeared in people with high cumulative exposure, generally more than a year of total daily doses added up over time. Occasional or short term use was not where the signal showed up. And cumulative means exactly that: every anticholinergic you take counts toward one running total, which is why a full medication list matters more than any single prescription does.
Should I stop taking oxybutynin if I am worried about dementia?
No, not on your own. Stopping suddenly leaves the bladder symptoms untreated, and those carry their own risks including falls. The useful move is to book a medication review and ask specifically about your total anticholinergic load, since that is what the research actually measured.
What else counts toward anticholinergic burden?
More than most people expect. Older antidepressants, first-generation antihistamines used for allergies or sleep, some muscle relaxants, certain Parkinson's drugs, and antipsychotics all carry anticholinergic activity, and over the counter products count the same as prescriptions. Your pharmacist can total it up from a complete list, which is why bringing one matters.
Sources
- Iyen B, Coupland C, Bell BG, et al. Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years. BMJ Medicine, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11580265/ (doi:10.1136/bmjmed-2023-000799)
- Coupland CAC, et al. Anticholinergic Drug Exposure and the Risk of Dementia. JAMA Internal Medicine, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6593623/
- Gray SL, et al. Cumulative Use of Strong Anticholinergics and Incident Dementia. JAMA Internal Medicine, 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4358759/
- Belessiotis-Richards C, et al. Systemic medications and dementia risk: a systematic umbrella review. Molecular Psychiatry, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12532590/ (doi:10.1038/s41380-025-03129-3)
- Chughtai B, Levin R, De E. Choice of antimuscarinic agents for overactive bladder in the older patient. Clinical Interventions in Aging, 2008. https://pmc.ncbi.nlm.nih.gov/articles/PMC2682382/
- Kranz J, Petzinger E, Geyer J. Brain penetration of the OAB drug trospium chloride is not increased in aged mice. World Journal of Urology, 2011. https://pmc.ncbi.nlm.nih.gov/articles/PMC3557395/
- Oxybutynin chloride extended-release tablets, FDA prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec4fd95f-16dc-4acf-b560-b67b7aaef08b
- Mirabegron extended-release tablets, FDA prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d22d3d12-8466-46db-bc19-d13e87c6115c&audience=consumer
- Noguchi N, et al. The Association Between Overactive Bladder and Falls and Fractures: A Systematic Review. Research and Reports in Urology, 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6223978/
- American Geriatrics Society 2023 updated AGS Beers Criteria. https://pubmed.ncbi.nlm.nih.gov/37139824/
This article provides general information about medication management and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before making changes to your medication schedule.
